Neuland Laboratories Ltd
NEULANDLABBSE 524558PharmaceuticalsMkt cap ₹27,580 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹642 Cr
YoY +119.2%QoQ -17.3%
Net profit · Q1 FY27
₹148 Cr
YoY +962.4%QoQ -30.6%
Net margin · Q1 FY27
23.0%
+18.3 pts vs Q1 FY26
Net profit · FY26
₹364 Cr
YoY +39.9%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 642 | 776 | 440 | 514 | 293 | +119.2% |
| Other income | 8.49 | 12.46 | 8.05 | 1.80 | 7.86 | +8.0% |
| Total income | 650 | 789 | 448 | 516 | 301 | +116.3% |
| Profit before tax | 198 | 288 | 54.48 | 129 | 17.57 | +1026.1% |
| Tax | 50.17 | 74.82 | 13.90 | 32.58 | 3.67 | +1267.0% |
| Net profit | 148 | 213 | 40.57 | 96.85 | 13.90 | +962.4% |
| Net margin | 23.0% | 27.4% | 9.2% | 18.8% | 4.8% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 2,023 | 1,477 | 1,559 | 1,191 | 951 | +37.0% |
| Other income | 30.17 | 20.51 | 12.54 | 9.75 | 2.08 | +47.1% |
| Total income | 2,053 | 1,497 | 1,571 | 1,201 | 953 | +37.1% |
| Profit before tax | 489 | 346 | 401 | 216 | 82.16 | +41.2% |
| Tax | 125 | 86.22 | 101 | 52.23 | 18.34 | +45.0% |
| Net profit | 364 | 260 | 300 | 164 | 63.82 | +39.9% |
| Net margin | 18.0% | 17.6% | 19.3% | 13.7% | 6.7% |
BIC's take
We haven't covered Neuland Laboratories Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 5:35 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.